PURE · XBRL financial data

PURE Bioscience financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (PURE's year ends in late July)

In thousands of dollars	FY 2021Jul 31, 2021	FY 2022Jul 31, 2022	FY 2023Jul 31, 2023	FY 2024Jul 31, 2024	FY 2025Jul 31, 2025	FY 2026Jul 31, 2026
Revenue	3,698	1,813	1,871	1,955	2,198	2,315
Revenue from contracts with customers	3,927	1,853	1,877	1,963	2,202	2,318
Cost of goods and services sold	1,852	853	906	811	899	992
Gross profit	2,075	1,000	971	1,152	1,303	1,326
Research and development	339	319	297	302	316	332
Selling, general and administrative	4,047	4,106	4,302	3,981	3,259	3,077
Total operating expenses	4,386	4,724	4,914	4,343	3,575	3,409
Operating income (loss)	(2,311)	(3,724)	(3,943)	(3,191)	(2,272)	(2,083)
Interest expense	4	6	14	155	299	407
Other income (expense)	(4)	—	(4)	(4)	172	7
Income tax expense (benefit)	2	2	2	0	0	0
Net income (loss)	(2,319)	(3,491)	(3,961)	(3,350)	(2,399)	(2,483)
Earnings per share, basic USD per share	(0.03)	(0.04)	(0.04)	(0.03)	(0.02)	(0.02)
Earnings per share, diluted USD per share	(0.03)	(0.04)	(0.04)	(0.03)	(0.02)	(0.02)
Weighted average shares, basic thousands of shares	87,174	88,835	111,404	111,856	111,863	116,457
Weighted average shares, diluted thousands of shares	87,174	88,835	111,404	111,856	111,863	116,457

Fiscal years (PURE's year ends in late July)

In thousands of dollars	FY 2021Jul 31, 2021	FY 2022Jul 31, 2022	FY 2023Jul 31, 2023	FY 2024Jul 31, 2024	FY 2025Jul 31, 2025	FY 2026Jul 31, 2026
Cash and cash equivalents	2,390	3,391	1,095	349	334	569
Accounts receivable	368	201	285	298	474	334
Inventory	332	179	88	56	141	193
Total current assets	3,197	3,864	1,604	805	1,047	1,185
Property and equipment, net	740	620	221	13	11	8
Total assets	4,303	4,484	1,825	818	1,058	1,193
Accounts payable	593	488	422	601	784	820
Accrued liabilities	138	87	110	132	154	170
Total current liabilities	970	575	532	733	938	4,371
Total liabilities	970	575	1,553	3,682	6,174	7,592
Accumulated deficit	(125,793)	(129,284)	(133,245)	(136,595)	(138,994)	(141,477)
Total stockholders' equity	3,333	3,909	272	(2,864)	(5,116)	(6,399)
Total liabilities and equity	4,303	4,484	1,825	818	1,058	1,193
Common shares outstanding (cover page) thousands of shares	87,223	111,356	111,856	111,856	111,886	140,201

Fiscal years (PURE's year ends in late July)

In thousands of dollars	FY 2021Jul 31, 2021	FY 2022Jul 31, 2022	FY 2023Jul 31, 2023	FY 2024Jul 31, 2024	FY 2025Jul 31, 2025	FY 2026Jul 31, 2026
Net income (loss)	(2,319)	(3,491)	(3,961)	(3,350)	(2,399)	(2,483)
Stock-based compensation	841	567	324	214	147	197
Net cash from operating activities	(1,167)	(2,418)	(3,278)	(2,531)	(2,015)	(1,738)
Purchases of property and equipment	521	81	33	—	—	—
Net cash from investing activities	(521)	(81)	(33)	—	—	—
Proceeds from issuing common stock	—	3,500	—	—	—	—
Net cash from financing activities	239	3,500	1,015	1,785	2,000	1,973
Net change in cash	(1,449)	1,001	(2,296)	(746)	(15)	235

SIC 2890 and related industry codes, similar size; rows marked “added: same SIC” fill a short list. Each row is the latest quarter reported.

How peers are chosen

SIC 2890 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Fewer than three companies fall in that range, so the list adds same-SIC (2890) companies nearest in public float, each marked “added: same SIC”.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Pure Bioscience	569	659*	(414)*	140.2M	1.4 quarters	Q4 FY26 10-KJul 31, 2026
NEXT-ChemXadded: same SIC	22	not reported	(329)*	28.5M	0.1 quarters	Q2 FY25 10-QJun 30, 2025
Flexible Solutions Internationaladded: same SIC	7,198	7,610	5,313*	12.8M	—	Q2 FY26 10-QJun 30, 2026
Flotek Industriesadded: same SIC	4,402	99,367	(6,601)*	36.2M	0.7 quarters	Q2 FY26 10-QJun 30, 2026
Arqadded: same SIC	7,752	38,209	10,344*	44.2M	—	Q3 FY26 10-QSep 30, 2026
ASP Isotopesadded: same SIC	219,596	5,123	(23,334)*	153.3M	10.9 quarters	Q2 FY26 10-QJun 30, 2026
Orionadded: same SIC	71,300	472,800	57,800*	56.5M	—	Q3 FY26 10-QSep 30, 2026
WD 40added: same SIC	70,607	176,780*	50,152*	13.4M	—	Q4 FY26 10-KAug 31, 2026
Element Solutionsadded: same SIC	224,900	995,300	159,200*	242.6M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.